ban

Court restricts mifepristone access nationwide

A federal appeals court has restricted access to one of the most common means of abortion in the U.S. by blocking mailing of mifepristone prescriptions.

Friday’s unanimous ruling from a three-judge panel of the New Orleans-based 5th U.S. Circuit Court of Appeals is requiring that the abortion pill be distributed only in person and at clinics, overruling regulations set by the federal Food and Drug Administration.

The ruling, which is likely to be appealed to the U.S. Supreme Court, is the biggest jolt to abortion policy in the U.S. since the 2022 Supreme Court ruling that overturned Roe vs. Wade and allowed states to enforce abortion bans.

In the ruling, Judge Kyle Duncan, who was appointed by President Trump, agreed with the state of Louisiana’s contention that allowing the drug to be mailed there makes moot the state’s ban on abortion at all stages of pregnancy.

“Every abortion facilitated by FDA’s action cancels Louisiana’s ban on medical abortions and undermines its policy that ‘every unborn child is a human being from the moment of conception and is, therefore, a legal person,’” the ruling states.

Commonplace treatment

Mifepristone was approved in 2000 as a safe and effective way to end early pregnancies. It is typically used in combination with a second drug, misoprostol.

Surveys have found that the majority of abortions in the U.S. are provided via pills and that about 1 in 4 abortions nationally are prescribed via telehealth.

One survey of abortion providers last year estimated that more women in states where abortion is banned obtained abortions that way than by traveling to other states.

Some Democratic-led states have laws that seek to protect providers who prescribe via telehealth to patients in places with bans.

That rise in prominence is why abortion opponents have targeted the pills in legislation and litigation.

Little precedent

There is little precedent for a federal court overruling the scientific regulations of the FDA, and it wasn’t immediately clear how quickly or completely the decision would affect mailing of the drug throughout the country.

Judges have long deferred to the agency’s judgments on the safety and appropriate regulation of drugs.

FDA officials under Trump have repeatedly stated that the agency is conducting a new review of mifepristone’s safety, at the direction of the president.

The judges, all nominated by Republican presidents, noted in their ruling that the FDA “could not say when that review might be complete and admitted it was still collecting data.”

Because of rare cases of excessive bleeding, the FDA initially imposed strict limits on who could prescribe and distribute the pill — only specially certified physicians and only after an in-person appointment where the person would receive the pill.

Both requirements were dropped during the COVID-19 emergency. At the time, FDA officials under President Biden said that after more than 20 years of monitoring mifepristone use, and reviewing dozens of studies involving thousands of women, it was clear that women could safely use the pill without direct supervision.

GenBioPro, which makes generic mifepristone, said in a statement that the court’s decision “ignores the FDA’s rigorous science and decades of safe use of mifepristone in a case pursued by extremist abortion opponents.”

Broader impact

In a court filing, Louisiana’s attorney general and a woman who said she was coerced into taking abortion pills requested that the FDA rules be rolled back to when the pills were allowed to be prescribed and dispensed only in person.

A Louisiana-based federal judge last month ruled that those allowances undermined the state’s abortion ban but stopped short of undoing the regulations immediately.

Friday’s ruling is in effect as the case works its way through the courts and extends beyond Louisiana and other states with abortion bans.

Telehealth prescriptions have become common even in states where abortion is allowed — and the ruling blocks them there, too.

“This is going to affect patients’ access to abortion and miscarriage care in every state in the nation,” said Julia Kaye, an ACLU lawyer. “When telemedicine is restricted, rural communities, people with low incomes, people with disabilities, survivors of intimate partner violence and communities of color suffer the most.”

The National Right to Life Committee said the ruling “restores a critical layer of oversight” in women’s health.

“Women deserve better than an abortion-by-mail system that prioritizes ideology over safety,” said Carol Tobias, the group’s president.

Next step

Friday’s ruling sets up a likely appeal to the Supreme Court.

“I look forward to continuing to defend women and babies as this case continues,” Louisiana Atty. Gen. Liz Murrill, a Republican, said in a statement.

The conservative-majority high court overturned abortion as a nationwide right in 2022 but unanimously preserved access to mifepristone two years later.

That 2024 decision sidestepped the core issues, however, by ruling that the antiabortion doctors behind the case didn’t have legal standing to sue.

Representatives for the FDA and the U.S. Department of Justice did not immediately respond to requests for comment Friday evening.

In the meantime, antiabortion groups are celebrating Friday’s ruling. Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, applauded the ruling as “a huge victory for victims and survivors of Biden’s reckless mail-order abortion drug regime.” She also criticized the Trump administration for taking time to conduct its own review of mifepristone, saying its slow movement has forced states to take action.

“Women and children suffer and state sovereignty is violated every day the FDA allows abortion drugs to flood the mail,” Dannenfelser said.

Mulvihill and Schoenbaum write for the Associated Press. AP writers John Hanna, Matthew Perrone and Lindsay Whitehurst contributed to this report.

Source link

Mykhailo Mudryk: Why was Chelsea winger given secret ban?

Mudryk has been suspended and unable to play for either Chelsea or Ukraine since the FA provisionally suspended him 16 months ago.

He remains contracted to the Blues until 2031, having signed a long deal when he joined for £61m in 2022, as part of the club’s plan to amortise the cost of transfers and contracts.

Amortisation means spreading costs out over many years in order to reduce them in each year of a business’ accounts.

If Mudryk’s ban is upheld by Cas, he would be unable to play again until roughly December 2028, as that is four years since his provisional suspension began.

But if the ban were to be reduced by Cas, he could be back on the pitch in a much shorter timeframe. Sources close to the player believe he could be back in action as early as next season.

Chelsea would be able to terminate Mudryk’s contract once the Cas process has concluded, given an anti-doping ban constitutes a breach of employment terms in most footballers contracts.

Were they to do that, the amortised cost of the remaining years of Mudryk’s contract would disappear from the club accounts – effectively writing the expense off and helping their finances significantly.

On the other hand though, Chelsea would be entitled to sell Mudryk for some sort of transfer fee if they maintain his contract and keep paying his wages.

Or they could of course continue to pay his wages as a member of their squad and reintegrate him into the team once the ban has ended.

Source link

Mykhailo Mudryk: Chelsea player appeals against FA drugs ban

Chelsea winger Mykhailo Mudryk has lodged an appeal with the Court of Arbitration for Sport against a four‑year drugs ban imposed by the Football Association.

The Ukraine international, 25, has been sidelined for nearly 18 months after an “adverse finding in a routine urine test” led to a provisional suspension in December 2024.

Charged in June 2025, Mudryk was subsequently handed the maximum four‑year ban by the FA, according to a spokesperson for the Court of Arbitration for Sport, the highest legal authority in sport.

The FA has never disclosed details of the case.

In such cases, bans are typically backdated to the start of the provisional suspension, meaning his current return date would be around December 2028.

However, an appeal has now been lodged with the Court of Arbitration for Sport (Cas) in Switzerland, with sources close to the player hopeful he could return to action as early as next season.

In a statement to BBC Sport, Cas said: “Cas confirms it has received an appeal by Mykhailo Mudryk against the FA, filed on 25 February 2026. The Parties are currently exchanging written submissions, and a hearing is yet to be scheduled.”

The BBC understands Mudryk came into contact with the cardiovascular medication meldonium, which can increase respiratory capacity and stamina, while on duty with the Ukraine national team in October 2024.

Mudryk, who joined Chelsea for an initial 70m euros (£61m) in January 2023, has not played a competitive match since November 2024.

In his only public statement when his provisional suspension began, Mudryk described his “complete shock” and said he had “never knowingly used any banned substances or broken any rules”.

Mudryk is being defended by Morgan Sports Law, the firm who worked with former Manchester United midfielder Paul Pogba during his doping case while playing for Juventus, as well as boxer Tyson Fury and cyclist Chris Froome during their respective investigations.

He is understood to want to return to playing football this year and is keeping fit by training at non-league Uxbridge FC with a private coach and having hired goalkeepers to work with.

Chelsea declined to comment as they wait for the process to take its full course and the FA said it is unable to comment on an ongoing case. Mudryk’s legal team has also been contacted for comment.

Source link

2026 World Snooker Championship: Neil Robertson calls for ban on Ronnie O’Sullivan’s Triangle Chalk

Former world champion Neil Robertson has called for a controversial chalk used by Ronnie O’Sullivan to be banned, saying most other players “hate it” and that it “makes an absolute mess of the table”.

O’Sullivan, 50, is one of only a handful of players on the World Snooker Tour (WST) to still use the traditional Triangle Chalk.

Critics say it causes more poor contacts, leading to ‘kicks’ when the cue ball hits the object ball, often resulting in players running out of position or missing pots.

Almost all players use Taom Chalk, which reduces kicks and leaves no marks on the table.

There are currently no restrictions in place on what chalks can be used in WST events so O’Sullivan, who lost a thrilling last-16 tie 13-12 to John Higgins earlier on Monday, has not done anything against the sport’s rules.

However, there was a noticeable kick in the deciding frame when the Scot was taking a shot on a red.

He could be heard saying “oh my god” when the cue ball did not run through as expected. That red was potted, but, out of position, Higgins then missed the following black, although it did not prove crucial as he sealed an incredible victory, having trailed 8-3 and 9-4.

Robertson won 13-7 in his last-16 match against Chris Wakelin to set up a meeting with Higgins, with the Australian pleased to avoid O’Sullivan – and his chalk.

“I would prefer to play John so I don’t have to contend with the chalk that Ronnie uses, which should be banned from the game,” Robertson told BBC Four.

“I don’t know how you are allowed to even use it.”

Source link